Pregnancy and Breastfeeding in Inflammatory Bowel DiseaseBiedermann L. · Rogler G. · Vavricka S.R. · Seibold F. · Seirafi M.
aDivision of Gastroenterology and Hepatology, University Hospital Zurich, bZurich Center for Integrative Human Physiology, University of Zurich, and cDivision of Gastroenterology and Hepatology, Triemlispital, Zurich, dDivision of Gastroenterology and Hepatology, Hospital Tiefenau, Spital Netz Bern, Berne, and eDivision of Gastroenterology and Hepatology, University Hospital Geneva, Geneva, Switzerland
Inflammatory bowel disease (IBD) is frequent in women during their peak reproductive years. Accordingly, a significant number of questions and uncertainties arise from this population regarding the risk of transmission of IBD to the offspring, the impact of the disease and therapies on the fertility, the role of the disease on the course of the pregnancy and the mode of delivery, the impact of the therapy on the pregnancy and fetal development as well as breastfeeding. The safety of medical therapy during pregnancy and lactation is a major concern for both pregnant women and their partners as well as for physicians. As a general rule, it can be stated that the benefit of continuing medical therapy in IBD during pregnancy outweighs the potential risks in the vast majority of instances. This article will review recent developments on this topic consistent with the European Crohn’s and Colitis Organization guidelines.
Luc Biedermann, MD
Division of Gastroenterology and Hepatology, University Hospital Zurich
CH–8091 Zurich (Switzerland)
Tel. +41 44 255 3642, E-Mail firstname.lastname@example.org
Published online: October 5, 2012
Number of Print Pages : 10
Number of Figures : 0, Number of Tables : 2, Number of References : 84
Digestion (International Journal of Gastroenterology)
Vol. 86, No. Suppl. 1, Year 2012 (Cover Date: October 2012)
Journal Editor: Göke B. (Munich), Shinomura Y. (Sapporo)
ISSN: 0012-2823 (Print), eISSN: 1421-9867 (Online)
For additional information: http://www.karger.com/DIG